Navigation Links
Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
Date:4/26/2013

MONROVIA, Calif., April 26, 2013 /PRNewswire/ -- Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 is a potent anti-CD19 monoclonal antibody Fc optimized for high cytotoxic function for which MorphoSys licensed exclusive worldwide rights from Xencor in 2010. The dosing of the first patient in the study triggers an undisclosed milestone payment to Xencor.

The US-based study is an open-label, multicenter, single-arm clinical trial designed to assess the efficacy of MOR208 in patients suffering from relapsed or refractory B-ALL. Secondary outcome measures include response duration, safety and pharmacokinetics of MOR208. In total, 30 patients are planned to be enrolled. More information on the trial can be found by searching for MOR208 at www.clinicaltrials.gov.

"Preclinical and early clinical studies of MOR208 have shown promising anti-tumor activity and supported this additional study in ALL as well as another study in Non Hodgkin's Lymphoma which is expected to start shortly," said Bassil Dahiyat , Ph.D., Chief Executive Officer of Xencor. "Xencor monoclonal antibody candidates continue to advance in clinical development and showcase the value of our XmAb® Fc technology."

MOR208 has shown in a Phase 1/2a trial encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition to the phase 2 trial in B-ALL MorphoSys is about to start a second Phase 2 trial in Non-Hodgkin's Lymphoma (NHL).

B-cell malignancies, such as B-ALL, NHL and CLL affect more than one hundred and fifty thousand patients in the seven major markets each year. The target molecule CD19
'/>"/>

SOURCE Xencor
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Clinical trial for rabies monoclonal antibody
2. New monoclonal antibody developed that can target proteins inside cancer cells
3. Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis
4. Flu antibody’s one-handed grab may boost effort toward universal vaccine, new therapies
5. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
6. Labor der Zukunft -- Tomorrows laboratory technology
7. The future of plant science - a technology perspective
8. The future of plant science a technology perspective
9. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
10. UF researchers look for ways to make an emerging technology safe for environment
11. Breast cancer risk gene discovery fast tracked by new technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The enormous conflagration known as the Rim Fire was ... among mature trees, when it entered the backcountry of ... August 2013. But inside the park, the battle began ... management decisions and drought can combine to fuel large, ... park, it eventually encountered lands where fire had been ...
(Date:7/31/2014)... Florida State University researcher found that bacteria in the ... of the oil released during the Deepwater Horizon spill ... most toxic contaminants. , In two new studies conducted ... found a species of bacteria called Colwellia ... and xylene compounds that were released as part of ...
(Date:7/31/2014)... July 31, 2014 NXT-ID, Inc., (NXTD: OTCQB) a ... market, reminds investors and consumers wanting to learn ... it will be on-air today, July 31 st ... wallet will be featured in a segment of ... that airs on the History Channel, FYI Network ...
Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3
... led by Johns Hopkins scientists has,found the first ... immune,system's remarkable ability to recognize and respond to ... family of genes whose,only apparent function is to ... cut themselves out of the genetic material, and ...
... Health Department today issued a public health advisory after reporting ... highly drug resistant strain of HIV in a New York ... have occurred in mid-October 2004, to a largely untreatable strain ... health officials, the man -- who had previously had five ...
... President and Director of Research at the ... ,the release of a new approach to simulation ... of Nature,Biotechnology.,The research article, entitled "Automatic generation ... ,describes MSI's discrete stochastic event simulator, which keeps ...
Cached Biology News:UCSD Discovery Shows How Embryonic Stem Cells Perform 'Quality Control' Inspections 2UCSD Discovery Shows How Embryonic Stem Cells Perform 'Quality Control' Inspections 3NYC's First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 3
(Date:7/31/2014)... reason people over 60 are not donor candidates for ... with time, making the elderly prone to life-threatening infection ... team now has discovered a reason why. , "We ... of blood-forming cells to maintain blood production over time ... that could be restored for rejuvenation therapies," said Emmanuelle ...
(Date:7/31/2014)... 31, 2014 The SNIS Foundation recognized ... to fund a translational research project.  The first ... gift was presented at the Society of NeuroInterventional ... Colorado Springs, CO. ... to neurovascular conditions, SNIS formed the SNIS Foundation, ...
(Date:7/31/2014)... 2014 According to a new ... Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ... Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry ... 2019," the global electrodes market for medical devices was ... estimated to reach a market worth USD 1,451.2 million ...
(Date:7/31/2014)... China , July 31, 2014 ... Irys™System by BGI , the world,s ... comprehensive exploration of human structural variation (SV) and to ... including those where no reference exists. In addition, BioNano ... for multiplexing on the Irys System, enabling significantly higher ...
Breaking Biology Technology:Key to aging immune system is discovered 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4
... H. Paul Dorman, Chairman,and Chief Executive Officer of ... has signed a definitive agreement to sell its,dermatology ... VRX )., Under the terms of ... shares of Coria from DFB Pharmaceuticals, Inc., and ...
... today announced that for the second year, it will ... hospitals, health systems and,community health clinics improve patient safety ... Patient Safety Grant Program in August,2007 as the first ... sector, and,received applications from more than 10 percent of ...
... 17 Quark Pharmaceuticals, Inc.,a development-stage ... interference (RNAi)-based therapeutics, today announced the,presentation ... RNAi Europe, taking place,September 16-18, 2008 ... scientists,Igor Mett, Hagar Kalinski, and Hagit ...
Cached Biology Technology:DFB Sells Coria Labs to Valeant Pharmaceuticals 2DFB Sells Coria Labs to Valeant Pharmaceuticals 3Cardinal Health Invites Health Care Providers to Apply for $1 Million in Grants to Fund Patient Safety Initiatives 2Cardinal Health Invites Health Care Providers to Apply for $1 Million in Grants to Fund Patient Safety Initiatives 3Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 2Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 3
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
Rabbit anti-Junctophilin-4 (C-term)...
... CopyControl™ PCR Cloning Kits are designed to speed ... that all PCR products, regardless of sequence or ... PCR products including those that are difficult to ... may be unstable or code for potentially detrimental ...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
Biology Products: